Entrada Therapeutics (TRDA) Tax Provisions (2023 - 2026)

Entrada Therapeutics' Tax Provisions history runs 4 years deep, the most recent figure standing at $38000.0 for Q1 2026.

• In Q1 2026, Tax Provisions changed N/A year-over-year to $38000.0; the TTM figure through Mar 2026 stood at $1.1 million (up 218.0% YoY), while the FY2025 annual figure was $924000.0, up 2.67% from the prior year.
• Tax Provisions was $38000.0 for Q1 2026 at Entrada Therapeutics, down from $124000.0 in the prior quarter.
• In the past five years, Tax Provisions ranged from a high of $18.7 million in Q4 2023 to a low of -$17.4 million in Q3 2023.
• Historically, Tax Provisions has averaged $1.7 million across 4 years, with a median of $450000.0 in 2025.
• The sharpest annual moves came in 2024 and 2025: Tax Provisions tumbled 109.63% in 2024, then jumped 136.84% in 2025.
• A 4-year view of Tax Provisions shows it stood at $18.7 million in 2023, then sank by 109.63% to -$1.8 million in 2024, then surged by 106.89% to $124000.0 in 2025, then plunged by 69.35% to $38000.0 in 2026.
• The last three Tax Provisions figures came in at $38000.0 (Q1 2026), $124000.0 (Q4 2025), and $700000.0 (Q3 2025), per Business Quant data.